GlassScriptPhysician profile
Dina Patel
NPI 1316499205
$1,581.16
in general payments reported to CMS, 2019-2025
14 companies · $992 in 2025
The $992 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $18.76 · 2022: $33.94 · 2023: $29.61 · 2024: $507 · 2025: $992.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,528.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,528.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Curonix LLC | $372.38 | 2024-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Abbvie INC. | $292.15 | 2023-2025 | |
| Pfizer INC. | $259.67 | 2024-2025 | |
| Collegium Pharmaceutical, INC. | $142.86 | 2024-2025 | Belbuca, Xtampza |
| Spinal Simplicity, LLC | $121.09 | 2025 | Ha Minuteman G3-R |
| Foundation Fusion Solutions, LLC | $113.54 | 2025 | |
| Medtronic, INC. | $86.40 | 2025 | Intellis Adaptivestim |
| Astrazeneca Pharmaceuticals LP | $51.50 | 2021-2023 | Lokelma |
| Axsome Therapeutics, INC. | $51.14 | 2025 | Symbravo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.45 | 2025 | Relistor |
| Merz Pharmaceuticals, LLC | $21.05 | 2025 | Xeomin |
| Azurity Pharmaceuticals, INC. | $16.83 | 2024 | |
| Opko Pharmaceuticals, LLC | $14.64 | 2022 | |
| Ardelyx, INC. | $14.46 | 2024 | Ibsrela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dina Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.